groton68,one BP partner for the entire Brilacidin platform certainly makes sense. Also consider that B-OM is (1) a unique formulation that is easily separated from the rest of the Brilacidin platform and (2) falls within Oncology. I'd suggest that an oncology focused pharma could do a clean deal for B-OM and K. Deals across multiple drug company divisions within a BP could take a lot longer than one or two products within a single large division.
IPIX will,imo, have a range of options moving forward and the resources to move the pipeline forward until the right deal is penned.
News 
Market Data 
Discover 
